multipl
sclerosi
ms
chronic
demyelin
diseas
affect
central
nervou
system
cn
princip
young
adult
although
etiolog
yet
unknown
current
evid
suggest
tissu
damag
mediat
autoimmun
cell
examin
experiment
anim
model
ms
experiment
allerg
encephalomyel
eae
demonstr
myelin
basic
protein
mbp
proteolipid
protein
plp
specif
cell
mediat
destruct
cn
myelin
recent
year
eleg
studi
eae
shown
encephalitogen
cell
recogn
short
peptid
mbp
plp
context
mhchlaclass
ii
molecul
express
restrict
number
cell
receptor
tcr
molecul
secret
interferon
tumor
necrosi
factorc
understand
pathogenet
step
lesion
develop
molecular
level
led
highli
specif
immunotherapi
eae
target
individu
molecul
hope
mani
investig
immunolog
event
resembl
eae
found
patient
ms
specif
immunotherapi
effect
eae
could
also
appli
ms
howev
date
evid
uniqu
immunolog
abnorm
ms
strong
although
mbpand
plpspecif
cell
properti
similar
encephalitogen
anim
isol
patient
specif
ms
occur
similar
frequenc
control
addit
variabl
specif
tcr
usag
rais
question
regard
relev
cell
patient
import
cell
respons
myelin
antigen
ms
may
establish
effect
abrog
activ
specif
therapi
target
trimolecular
complex
tmc
demonstr
consequ
attent
begun
focu
modifi
biolog
ms
lesion
rather
target
initi
event
level
tmc
success
approach
reflect
effect
lesion
develop
ms
recent
approv
use
treatment
relapsingremit
ms
rais
great
interest
examin
novel
strategi
immunotherapi
ms
correspond
h
mcfarland
r
martin
h
mcfarland
basic
concept
well
current
candid
new
immunotherapi
outlin
short
review
etiolog
multipl
sclerosi
ms
known
current
believ
autoimmun
cell
specif
myelin
antigen
involv
pathogenesi
although
evid
immunolog
mechan
larg
circumstanti
becom
increasingli
convinc
patholog
ms
resembl
associ
immunolog
mediat
diseas
patient
benefici
effect
immunosuppress
therapi
seen
similar
ms
experiment
autoimmun
demyelin
diseas
experiment
allerg
encephalomyel
eae
support
autoimmun
process
ms
clear
differ
form
eae
induc
differ
suscept
anim
strain
reflect
clinic
histopatholog
immunolog
featur
ms
eae
nevertheless
excel
model
led
better
understand
pathogenet
step
lead
demyelin
chronicrelaps
form
eae
sjl
mous
diseas
exacerb
remit
ms
patholog
character
inflamm
demyelin
lesion
differ
age
bear
strong
resembl
seen
ms
crucial
rememb
howev
studi
use
eae
model
may
provid
import
clue
regard
potenti
treatment
ms
experiment
treatment
eae
mostli
initi
period
diseas
induct
even
treatment
amelior
subsequ
cours
use
diseas
establish
oper
condit
consider
differ
ms
therapi
usual
begun
long
diseas
start
evid
deriv
magnet
reson
imag
mri
studi
indic
even
time
initi
clinic
episod
mani
patient
show
multipl
lesion
indic
consider
previou
central
nervou
system
cn
inflamm
base
evid
eae
model
gener
regard
caus
potenti
therapi
ms
made
first
possibl
ms
like
eae
caus
cell
recogn
antigen
found
cn
although
studi
eae
focus
two
encephalitogen
protein
myelin
myelin
basic
protein
mbp
proteolipid
protein
plp
sever
antigen
includ
protein
present
predominantli
astrocyt
myelin
found
caus
enceph
although
sometim
without
demyelin
addit
cell
respons
virus
persist
cn
theiler
viru
corona
viru
ratadapt
measl
viru
also
produc
eaelik
pictur
ms
uncertain
whether
immun
respons
one
antigen
trigger
diseas
whether
relev
antigen
vari
patient
patient
eae
immun
respons
multipl
myelin
antigen
may
occur
diseas
progress
myelin
breakdown
occur
thu
ms
autoimmun
respons
direct
multipl
cn
myelin
antigen
could
contribut
diseas
sinc
gener
concept
activ
myelinspecif
cell
lesion
develop
deriv
eae
studi
ms
patholog
find
shall
briefli
summar
known
long
time
outbr
anim
mice
highli
resist
induct
eae
wherea
diseas
easili
induc
certain
inbr
rodent
strain
factor
close
associ
diseas
suscept
member
major
histocompat
complex
mhc
class
ii
gene
famili
ie
certain
iaand
iemhc
molecul
eg
ia
sjl
mous
examin
influenc
mhc
class
ii
molecul
demonstr
particular
peptid
deriv
myelin
antigen
preferenti
recogn
encephalitogen
variou
anim
strain
portion
specifc
myelin
protein
ie
mbp
encephalitogen
differ
speci
strain
influenc
mhc
makeup
anim
anoth
import
find
eae
encephalitogen
cell
lewi
rat
plj
mice
preferenti
use
limit
set
cell
receptor
tcr
chain
plj
mice
mice
recognit
complex
form
diseaseassoci
mhc
class
ii
molecul
encephalitogen
peptid
relationship
diseas
trimolecular
complex
tmc
compris
tcr
mhc
molecul
autoantigen
peptid
led
innov
therapeut
approach
target
compon
specif
block
mhc
molecul
nonstimulatori
modifi
encephalitogen
peptid
unrel
peptid
high
bind
affin
well
cell
vaccin
tcr
peptid
vaccin
success
eae
model
whether
similar
approach
success
ms
certain
sinc
relationship
specif
tcr
diseas
yet
clear
ms
eae
model
consid
event
result
induct
autoimmun
reaction
like
myelinspecif
cell
activ
peripheri
conclus
support
fact
cell
specif
number
myelin
antigen
demonstr
anim
induct
eae
also
healthi
human
individu
furthermor
shown
encephalitogen
cell
line
tcl
gener
repeat
stimul
mbp
lymph
node
cell
healthi
lewi
rat
marmoset
find
demonstr
autoreact
cell
compon
cell
repertoir
healthi
individu
also
potenti
mediat
demyelin
diseas
usual
either
activ
suppress
encount
target
autoantigen
proper
costimulatori
environ
suffici
express
antigen
although
natur
stimuli
lead
activ
myelinreact
cell
ms
yet
poorli
understood
either
virus
bacteri
superantigen
could
result
activ
autoantigenspecif
cell
virus
could
also
contribut
tissu
tropism
induc
upregul
express
necessari
adhes
costimulatori
molecul
target
organ
follow
activ
first
event
lesion
develop
appear
adhes
activ
cell
endotheli
cell
postcapillari
venul
preferenti
periventricular
white
matter
rel
import
interact
cell
adhes
molecul
cam
selectin
express
endotheli
cell
ligandson
encephalitogen
cell
yet
complet
understood
major
studi
demonstr
upregul
constitut
express
cam
selectin
endotheli
cell
earli
phase
lesion
develop
need
upregul
cam
requir
cell
adher
transmigr
current
unresolv
abil
activ
cell
transmigr
endotheli
cell
brain
parenchyma
clearli
demonstr
rat
mous
indic
whichev
cam
express
constitut
suffici
process
relationship
encephalitogen
express
late
antigen
vla
identifi
plp
mbpspecif
cell
antibodi
reduc
sever
eae
express
vascular
cam
vcam
howev
usual
high
acut
activ
lesion
increas
chronic
activ
lesion
suggest
occur
later
stage
lesion
evolut
intercellular
adhes
molecul
icam
ligand
lymphocyt
express
low
level
constitut
effort
block
diseas
antibodi
met
variabl
success
investig
report
effect
other
observ
worsen
diseas
effect
seem
relat
dose
rack
unpublish
result
time
antibodi
given
like
interact
selectin
suffici
cell
allow
initi
adhes
endotheli
cell
whether
cell
transmigr
endotheli
cell
barrier
whether
local
upregul
addit
cell
cam
occur
known
interferon
ifn
tumor
necrosi
factor
tnf
ct
secret
activ
encephalitogen
cell
upregul
cam
mhc
class
molecul
endotheli
cell
present
mbp
mbpspecif
cell
vitro
result
lysi
endotheli
cell
mhc
express
cell
upregul
import
antigen
present
level
endotheli
cell
eae
ms
unknown
cell
encount
target
antigen
remain
cn
initi
inflammatori
respons
adopt
transfer
mbpsensit
cell
label
indic
cell
found
lesion
earli
stage
lesion
develop
label
cell
tend
remain
perivascular
cuff
suggest
antigen
present
take
place
perivascular
area
result
consist
histochemistri
polymeras
chain
reaction
pcr
amplif
studi
tcr
express
encephalitogen
cell
affect
tissu
demonstr
presenc
specif
cell
earli
cours
inflamm
lesion
progress
secondarili
recruit
cell
far
outnumb
encephalitogen
cell
thu
cell
enter
cn
initi
encount
antigen
induc
cascad
proinflammatori
cytokin
lead
activ
endothelium
recruit
addit
inflammatori
cell
includ
macrophag
among
factor
secret
tissu
autoantigenspecif
cell
tnfc
lymphotoxin
tnfcdlt
probabl
import
one
tnfc
ifn
involv
differenti
thl
cell
upregul
mhc
antigen
adhes
molecul
endotheli
cell
put
antigenpres
cell
apc
cn
recruit
activ
cell
mononuclear
phagocyt
furthermor
tnfc
mediat
direct
toxic
myelin
membran
oligodendrocyt
actual
effector
mechan
caus
demyelin
uncertain
could
includ
abovement
effect
tnfc
ifn
reactiv
oxygen
nitrogen
intermedi
secret
macrophag
upon
activ
final
myelinspecif
autoantibodi
may
enter
inflammatori
site
open
bloodbrain
barrier
bbb
secret
local
plasma
cell
may
mediat
attach
activ
macrophag
myelin
molecul
myelinassoci
glycoprotein
mag
myelin
oligodendrocyt
glycoprotein
mog
integr
part
myelin
membran
experiment
evid
mechan
exist
inflammatori
respons
cn
parenchyma
probabl
termin
apoptosi
infiltr
antigenspecif
nonspecif
cell
situ
thu
sever
stage
lesion
develop
target
therapeut
list
tabl
discuss
current
direct
treatment
ms
examin
respect
phase
lesion
develop
target
treatment
sinc
specif
immun
respons
produc
diseas
known
use
gener
case
druginduc
immunosuppress
continu
import
approach
treatment
ms
larg
number
gener
immunosuppress
treatment
studi
list
tabl
evid
signific
effect
agent
margin
often
controversi
mani
trial
immunosuppress
drug
report
show
effect
question
method
appli
problem
identifi
use
immunosuppress
drug
may
question
difficulti
conduct
clinic
trial
ms
real
lack
effect
drug
immunosuppress
drug
test
trial
involv
patient
chronic
progress
ms
cpm
sinc
relationship
potenti
risk
possibl
benefit
thought
clearer
howev
outcom
measur
patient
alreadi
suffer
consider
disabl
difficult
progress
diseas
patient
popul
may
also
relat
mechan
axon
degener
complic
assess
result
difficulti
may
overcom
trial
involv
larger
number
patient
long
period
treatment
usual
imposs
expens
interest
recent
meta
analysi
variou
trial
use
azathioprin
indic
drug
effect
reduc
progress
disabl
sinc
role
antigenspecif
suppress
uncertain
inabl
identifi
caus
agent
specif
myelin
antigen
pathogenet
relev
individu
patient
gener
immunosuppress
may
remain
import
part
therapi
ms
hope
studi
use
mri
outcom
measur
permit
assess
drug
shorter
studi
period
thu
limit
potenti
risk
treatment
effect
patient
milder
relaps
remit
ms
rrm
examin
although
understand
antigen
cell
involv
myelinspecif
cell
respons
greatli
increas
recent
year
antigen
antigen
target
immunopatholog
process
specif
patient
group
ms
patient
still
poorli
understood
experiment
therapi
built
probabl
protein
strong
encephalitogen
potenti
experiment
anim
mbp
plp
like
candid
antigen
ms
increas
number
mbpand
plpspecif
cell
peripher
blood
cerebrospin
fluid
ms
patient
base
assumpt
therapi
design
block
elimin
respons
undertaken
design
tabl
therapi
target
tmc
lead
number
potenti
outcom
includ
block
activ
induct
anergi
toler
rather
activ
induct
program
cell
death
apoptosi
chang
function
characterist
cell
either
longer
mediat
diseas
possibl
even
target
suppress
cell
lesion
specif
therapi
direct
compon
tmc
ie
antigen
peptid
tcr
mhc
class
ii
molecul
present
antigen
peptid
tcr
attempt
inactiv
mbpspecif
cell
eae
stimul
potenti
exist
regulatori
suppress
network
date
back
earli
cohen
cowork
administ
inactiv
encephalitogen
line
cell
cell
vaccin
later
shown
cell
vaccin
may
either
direct
molecul
specif
encephalitogen
cell
like
tcr
idiotyp
activ
molecul
encepbalitogen
cell
antiergotyp
therapi
presenc
vivo
activ
cell
directli
lyse
encephalitogen
line
cell
suppress
diseas
demonstr
later
recent
studi
ms
patient
demonstr
administr
inactiv
mbpspecif
cell
clone
induc
popul
idiotypespecif
cell
also
result
reduct
precursor
frequenc
number
mbpspecif
cell
shortli
demonstr
regulatori
cell
eae
vitro
becam
clear
encephalitogen
cell
lewi
rat
well
b
plj
mice
although
recogn
differ
mbp
peptid
context
differ
restrict
element
express
restrict
tcr
repertoir
predomin
express
chain
also
limit
number
c
chain
observ
led
success
applic
monoclon
antibodi
direct
also
allow
develop
therapi
employ
administr
peptid
deriv
tcr
chain
rather
inject
inactiv
whole
cell
popul
tcr
peptid
either
deriv
region
variabl
chain
molecul
complementar
determin
region
junction
region
tcr
rational
use
peptid
immun
peptid
chain
share
cell
bear
inher
problem
everi
immun
respons
employ
would
affect
second
approach
use
peptid
assum
target
area
tcr
known
interact
antigen
peptid
rather
mhc
molecul
would
suitabl
tailor
specif
cell
react
known
encepalitogen
peptid
strategi
effect
eae
therapi
base
immun
peptid
presum
act
induct
regulatori
cell
tcr
interfer
antigenpresent
analogu
peptid
interfer
cell
apc
conjug
antibodi
hlaclass
ii
antigen
interfer
antigenpresent
class
iirestrict
cell
mhcblock
peptid
interfer
antigen
present
antibodi
complex
diseaseassoci
mhc
class
ii
antigen
encephalitogen
peptid
exact
mechan
action
known
immun
peptid
deriv
third
hypervari
region
diseaseassoci
mhc
class
ii
antigen
induct
antibodi
portion
diseaserel
mhc
class
ii
antigen
ceil
vaccin
tcr
peptid
vaccin
induct
regulatori
ceil
phenotyp
well
antibodi
portion
tcr
anergi
induct
peptidemhc
complex
membran
fraction
apc
prepuls
encephalitogen
antigen
fix
apc
coupl
myelin
antigen
oral
toler
dosedepend
induct
anergi
andor
activ
suppress
mechan
includ
tgffl
secret
cell
administr
alter
peptid
ligand
base
encephalitogen
peptid
induct
anergi
function
antagon
highdos
iv
inject
myelin
antigen
lead
apoptot
death
preactiv
encephalitogen
cell
alter
peptid
ligand
base
encephalitogen
immunodomin
peptid
may
includ
phenotyp
switch
encephalitogen
cell
thl
cell
sinc
know
antigen
cell
popul
relev
individu
ms
patient
current
specul
whether
tcr
peptid
vaccin
ever
use
ms
might
necessari
tailor
individu
therapi
patient
howev
evid
specif
tcr
usag
exampl
mbpspecif
cell
subgroup
patient
show
similar
furthermor
number
epitop
recogn
heterogen
tcr
express
probabl
smaller
earli
stage
diseas
final
find
restrict
tcr
usag
brain
ms
patient
well
skew
tcr
repertoir
observ
ident
twin
discord
ms
argu
involv
cell
pathogenesi
ms
suggest
specif
immunotherapi
target
subset
cell
might
feasibl
certain
stage
diseas
welldefin
subgroup
patient
even
tcr
usag
encephalitogen
cell
studi
becam
clear
suscept
develop
eae
variou
anim
strain
larg
relat
mhc
class
type
furthermor
depend
diseaseassoci
mhc
class
ii
phenotyp
differ
region
encephalitogen
protein
mbp
encephalitogen
differ
strain
exampl
amino
acid
aa
ac
b
plj
mice
aa
sjlj
mice
aa
lewi
rat
base
observ
number
eleg
studi
shown
modif
encephalitogen
peptid
capabl
bind
restrict
element
high
affin
induc
encephalitogen
respons
block
eae
could
also
achiev
high
affin
bind
peptid
complet
unrel
encephalitogen
howev
approach
number
problem
theoret
blockad
avail
mhc
class
ii
molecul
exampl
homozygot
individu
could
result
gener
immunosuppress
although
seem
case
experiment
therapi
mhcblock
peptid
recent
shown
peptid
concentr
necessari
achiev
mhc
blockad
vivo
maintain
long
period
time
recent
larg
multicent
trial
examin
effect
copl
polypeptid
compos
four
aa
tyrosin
lysin
alanin
glutam
acid
random
sequenc
trial
earli
rrm
patient
show
small
signific
therapeut
effect
earlier
report
claim
block
eae
via
induct
mbpspecif
suppressor
cell
recent
data
suggest
block
antigenpresent
interf
bind
antigen
peptid
diseaseassoci
mhcclass
ii
molecul
vitro
although
addit
evid
mechan
account
effect
diseas
vivo
need
addit
monoclon
antibodi
diseaserel
mhc
class
ii
antigen
success
appli
problem
mention
induct
xenogen
antibodi
prevent
approach
human
recent
studi
anim
vaccin
peptid
deriv
third
hypervari
region
diseaseassoci
mhc
class
ii
antigen
ia
fl
chain
effect
treat
eae
via
induct
autoantibodi
specif
ia
chain
final
monoclon
antibodi
gener
antigenia
complex
also
block
diseas
experiment
therapi
also
success
target
tmc
eae
either
includ
inactiv
carrier
cell
spleen
cell
coupl
antigen
solubl
mhcpeptid
complex
administr
membran
fragment
cell
prepuls
protein
r
martin
h
mcfmland
method
led
anerg
state
sinc
encephalitogen
cell
properli
activ
absenc
costimulatori
signal
state
transient
longterm
unrespons
result
anergi
could
also
achiev
intrathym
inject
antigen
either
neonat
adult
anim
administr
bacteri
superantigen
result
either
delet
activ
cell
use
tcr
recogn
superantigen
treatment
superantigen
reduc
diseas
inject
eae
initi
strategi
obvious
applic
human
howev
anergi
also
induc
intraperiton
administr
encephalitogen
peptid
result
improv
cours
eae
rechalleng
antigen
recent
shown
eae
influenc
therapeut
induct
program
cell
death
encephalitogen
cell
therapeut
strategi
base
find
preactiv
cell
vigor
prolifer
presenc
undergo
apoptosi
rechalleng
antigen
observ
provid
basi
treat
anim
induct
eae
high
dose
mbp
therapeut
effect
due
apoptot
death
preactiv
encephalitogen
cell
could
demonstr
situat
time
dose
administr
apoptot
signal
prove
critic
outcom
obviou
variou
therapeut
strategi
outlin
specif
target
one
specif
cell
clone
bear
one
tcr
other
nonspecif
result
gener
immunosuppress
solut
problem
may
found
therapeut
concept
call
tcr
antagon
year
ago
sett
cowork
observ
modifi
antigen
peptid
abl
partial
block
complet
antagon
stimulatori
signal
mediat
recognit
nativ
peptid
present
context
appropri
mhc
previou
view
cell
receiv
either
posit
signal
tcr
engag
peptidemhc
complex
signal
complex
recogn
explain
number
find
follow
first
observ
meantim
sever
studi
confirm
result
shown
tcr
antagonist
alter
peptid
ligand
apl
either
mediat
signal
major
tcr
contact
site
antigen
peptid
modifi
caus
partial
respons
latter
situat
apl
peptid
abl
induc
lymphokin
releas
cytolysi
thl
cell
respect
without
concomit
prolifer
review
see
certain
substitut
even
caus
phenotyp
switch
ie
thl
cell
longer
secret
ifn
tnflt
produc
cytokin
instead
vergelli
et
al
prepar
great
advantag
tcr
antagon
offer
blockad
diseaseassoci
mhc
antigen
highaffin
binder
tcr
vaccin
effect
molar
rang
order
magnitud
use
mhc
blockad
specif
target
one
cell
popul
broad
rang
cell
latter
notion
alreadi
confirm
studi
kuchroo
et
al
sjl
mice
show
tcr
antagonist
peptid
base
encephalitogen
plp
peptid
block
eae
induc
number
encephalitogen
plp
cell
hybridoma
although
cell
express
differ
tcr
molecul
tcr
antagon
also
achiev
lewi
rat
eae
inject
solubl
apl
peptid
although
biolog
effect
caus
peptid
yet
entir
understood
could
act
induct
anergi
antagon
stimulu
nativ
peptid
induc
phenotyp
switch
respons
encephalitogen
peptid
anoth
approach
recent
studi
intens
origin
observ
rout
administr
oral
feed
inhal
antigen
result
immun
respons
drastic
differ
intraven
intramuscular
subcutan
immun
oral
administr
mbp
exampl
establish
state
toler
depend
dose
protein
fed
due
cell
anergi
higher
dose
induct
regulatori
cell
secret
transform
growth
lower
dose
addit
oral
administr
mbp
abl
crossprotect
plpinduc
eae
sjl
mice
oral
toler
current
test
number
experiment
human
autoimmun
diseas
includ
uveiti
insulindepend
diabet
rheumatoid
arthriti
ms
preliminari
result
pilot
trial
oral
toler
bovin
myelin
ms
patient
report
suggest
efficaci
group
male
patient
sinc
durat
trial
short
treatment
efficaci
control
mri
earli
draw
conclus
data
larg
placebocontrol
doubleblind
multicent
trial
current
way
confirm
interest
experiment
data
although
directli
involv
tmc
serv
import
accessori
function
recognit
antigen
cell
therefor
time
ago
attempt
made
interfer
encephalitogen
cell
use
monoclon
antibodi
molecul
stabil
conjug
cell
mhc
molecul
apc
monoclon
antibodi
abl
block
eae
human
monoclon
current
test
ms
patient
europ
initi
result
trial
show
antibodi
well
toler
format
interf
antibodi
problem
antibodi
success
deplet
cell
peripher
blood
patient
recent
publish
studi
employ
analogu
design
damino
acid
approach
also
abl
block
eae
howev
anticip
therapi
interfer
molecul
involv
gener
helper
cell
function
eventu
result
broad
immunosuppress
evid
deriv
studi
eae
model
examin
patholog
acut
lesion
well
mri
studi
ms
patient
indic
initi
event
develop
new
ms
lesion
breakdown
bbb
event
like
associ
transmigr
lymphocyt
activ
peripheri
brain
spinal
cord
parenchyma
rel
import
properti
cell
compar
express
adhes
molecul
endotheli
cell
region
inflammatori
infiltr
preferenti
develop
ie
around
small
postcapillari
venul
periventricular
white
matter
unresolv
evid
studi
rat
mous
indic
activ
cell
transmigr
brain
regardless
specif
cell
specif
myelin
glial
antigen
encount
target
autoantigen
cn
retain
cell
specif
tend
leav
sequenti
immunohistolog
pcr
studi
follow
express
tcr
chain
cn
tissu
adopt
transfer
welldefin
myelinspecif
tcl
demonstr
encephalitogen
cell
tcr
found
first
massiv
recruit
cell
receptor
presum
specif
occur
cell
express
tcr
encephalitogen
tcl
stay
longer
either
leav
die
situ
apoptosi
activ
cell
express
increas
level
sever
adhes
molecul
selectin
exampl
relationship
describ
encephalitogen
cell
rais
encephalitogen
determin
mbp
plp
express
ligand
cell
express
high
level
abl
transfer
eae
without
manipul
mous
presum
cell
cross
bbb
easili
antibodi
integrin
diminish
clinic
patholog
sever
eae
interact
cell
import
transmigr
encephalitogen
express
must
upregul
sinc
express
low
level
endotheli
cell
although
constitut
express
higher
level
cn
endotheli
cell
also
upregul
initi
stage
lesion
develop
could
contribut
cell
adhes
subsequ
transmigr
howev
treatment
eae
antibodi
ligand
produc
variabl
result
depend
time
dose
monoclon
antibodi
outcom
either
benefici
unalt
deleteri
also
import
note
cam
may
contribut
cellcel
interact
endotheli
cell
engag
structur
may
provid
activ
signal
cell
stimul
purifi
treatment
consid
patient
care
design
studi
experiment
system
address
question
one
also
determin
whether
phenotyp
function
differ
variou
cell
popul
cultiv
exampl
stimul
mbp
ms
patient
control
studi
compar
mbpspecif
cytotox
prolif
tcl
could
find
slightli
higher
express
differ
vergelli
et
al
unpublish
observ
although
human
mbpspecif
tcl
hand
larg
thl
cell
like
mediat
eae
variou
eae
system
clear
whether
specif
subpopul
pathogenet
import
anoth
respect
treatment
trial
ms
use
human
antibodi
differ
adhes
molecul
enter
enter
clinic
test
see
tabl
sinc
treatment
type
would
expect
affect
occurr
new
lesion
mri
provid
valuabl
tool
monitor
effect
therapi
tabl
therapi
target
adhes
autoantigen
cell
brain
endothelium
entri
parenchyma
antibodi
antibodi
antibodi
antibodi
vcami
overwhelm
evid
eae
mediat
sole
transfer
thl
cell
cell
mediat
delayedtyp
hypersensit
respons
tissu
inflamm
variou
infecti
diseas
character
lymphokin
secret
profil
ie
secret
ifn
tnfc
lymphotoxinc
lt
well
abil
lyze
antigenpres
target
cell
mention
encephalitogen
cell
thl
cell
human
mbpspecif
cell
probabl
also
phenotyp
thlderiv
lymphokin
contribut
amplif
local
inflammatori
respons
tissu
damag
number
way
well
known
ifn
upregul
mhc
antigen
adhes
molecul
express
number
cell
includ
endotheli
cell
glial
cell
cell
lymphoid
lineag
addit
ifn
drive
differenti
effector
cell
well
macrophag
stimul
releas
cytocid
reactiv
oxygen
nitrogen
intermedi
phagocyt
cell
astrocyt
besid
ifn
import
molecul
skew
cell
respons
direct
thl
respons
anoth
thl
lymphokin
famili
consist
primarili
macrophagederiv
tnfc
cellderiv
lt
also
contribut
inflammatori
process
besid
mediat
effect
similar
ifn
tnflt
shown
damag
endotheli
cell
result
chang
bbb
oligodendrogli
cell
lead
demyelin
tnflt
produc
local
inflammatori
plaqu
cn
eae
ms
respect
plaqu
develop
current
hypothes
encephalitogen
cell
adher
cn
endotheli
cell
upregul
class
ii
antigen
adhes
molecul
express
bbb
thu
facilit
transmigr
addit
may
directli
damag
endotheli
cell
allow
influx
serum
compon
contribut
tissu
damag
enhanc
local
inflammatori
process
via
promot
recruit
activ
incom
resid
cell
mention
tnflt
shown
damag
oligodendrogli
cell
vitro
thu
may
contribut
demyelin
import
tnflt
underlin
effect
monoclon
antibodi
tnflt
effect
block
eae
strategi
aim
inactiv
thl
lymphokin
includ
administr
solubl
tnf
receptorimmunoglobin
fusion
protein
monoclon
antibodi
target
macrophagederiv
proinflammatori
cytokin
upregul
thl
respons
administ
solubl
receptor
approach
success
treat
eae
import
proinflammatori
cytokin
ms
stem
number
observ
patient
therapi
ifn
result
increas
exacerb
level
tnflt
report
increas
blood
csf
ms
patient
relaps
latter
observ
howev
still
controversi
sinc
studi
confirm
find
furthermor
known
solubl
tnf
difficult
determin
bodi
fluid
tissu
sampl
sinc
secret
tnf
rapidli
induc
shed
tnf
receptor
consequ
format
tnftnf
receptor
complex
situat
hard
determin
lymphokin
level
reliabl
sinc
administr
monoclon
antibodi
costli
caus
number
problem
longterm
treatment
consider
interest
identifi
approach
interfer
product
tnflt
ifn
shown
phosphodiesteras
pde
inhibitor
abl
block
lymphocyt
activ
secret
tnfc
ifn
via
increas
intracellular
camp
level
group
agent
separ
phosphodiesteras
inhibitor
rel
nonspecif
action
pentoxifyllin
specif
block
certain
pde
type
member
latter
group
pde
type
iv
inhibitor
rolipram
particularli
attract
number
reason
contrast
unspecif
pde
inhibitor
pde
type
iv
almost
exclus
express
cn
lymphoid
cell
thu
significantli
less
side
effect
drug
origin
develop
test
antidepress
also
potent
suppress
effect
tnf
lesser
extent
secret
pentoxifyllin
effect
eae
pde
type
iv
inhibitor
rolipram
could
block
tnfand
ifn
secret
human
mbpspecif
cell
stereospecif
manner
also
inhibit
eae
lewi
rat
sjl
mice
sommer
et
al
prepar
also
marmoset
eae
model
sinc
substanc
side
effect
administ
oral
provid
attract
altern
treatment
monoclon
antibodi
solubl
tnf
receptor
anoth
interest
approach
interfer
tnf
employ
inhibitor
metalloproteas
enzym
usual
matrix
bound
exampl
gelatinas
b
cleav
membranebound
tnf
cell
membran
thu
releas
inflammatori
site
inhibitor
metalloproteas
capabl
inhibit
eae
repres
attract
altern
abovement
strategi
interfer
thl
lympkokin
ifnfl
recent
approv
treatment
rrm
also
belong
group
treatment
interfer
proinflammatori
cytokin
action
differ
level
includ
express
adhes
molecul
mhc
antigen
recruit
cell
lesion
process
antigen
present
induct
effector
stage
therapi
summar
tabl
tabl
therapi
modifi
effector
function
autoantigenspecif
cell
ie
upregul
adhes
mhc
class
molecul
express
activ
macrophag
resid
glial
cell
unspecif
interfer
activ
interferonbeta
transform
growth
factorbeta
solubl
tnf
receptor
immunoglobulin
fusion
protein
antibodi
tnflt
phosphodiesteras
inhibitor
rolipram
pentoxifyllin
inhibitor
induc
nitric
oxid
synthas
aminoguanidin
metalloproteas
inhibitor
number
cytokin
identifi
appear
downregul
inflamm
one
potent
shown
immunosuppress
effect
cell
b
cell
natur
killer
cell
decreas
leukocyt
transmigr
blood
vessel
inflammatori
site
treatment
anim
immun
myelin
antigen
antibodi
demonstr
accentu
diseas
also
examin
abil
directli
modifi
clinic
patholog
cours
eae
administ
prior
onset
clinic
diseas
mice
adopt
immun
cell
sensit
mbp
significantli
reduc
sever
clinic
diseas
produc
mark
reduct
inflamm
demyelin
patholog
immunohistochemistri
indic
decreas
express
mhc
class
ii
molecul
proinflammatori
cytokin
tnfc
administr
onset
diseas
also
reduc
sever
number
subsequ
relaps
also
demonstr
amelior
diseas
feed
antigen
oral
toler
induc
cell
secret
tgf
togeth
find
indic
profound
immunoregulatori
effect
cellmedi
autoimmun
diseas
eae
despit
encourag
initi
result
use
tgf
eae
extrapol
human
diseas
must
done
caution
sinc
thought
augment
inflammatori
condit
tissu
fibrosi
may
upregul
express
cam
clinic
phase
trial
ms
patient
assess
safeti
potenti
efficaci
system
administ
begun
nation
institut
health
addit
tgffl
cytokin
produc
cell
appear
downregul
antagon
thlmediat
inflamm
administr
adopt
transfer
eae
model
sjl
mice
shown
reduc
clinic
diseas
sever
reduc
product
proinflammatori
cytokin
produc
thl
cell
diet
enrich
retino
acid
also
amelior
eae
mous
rat
recent
evid
suggest
mechan
may
involv
upregul
cytokin
present
clear
mechan
retino
acid
entir
due
increas
product
along
line
express
increas
sever
time
cn
mice
recov
exacerb
eae
indic
endogen
secret
lymphokin
critic
recoveri
cn
inflamm
modul
experiment
autoimmun
diseas
immunoregulatori
cytokin
reflect
possibl
use
modifi
human
diseas
ms
manner
rather
immunomodulatori
gener
immunosuppress
outlin
activ
macrophag
toxic
radic
secret
cell
well
cytokin
produc
macrophag
lymphocyt
particular
tnflt
respons
demyelin
number
approach
mention
interfer
thl
lymphokin
also
act
level
decreas
activ
macrophag
consequ
also
extent
demyelin
administr
immunoglobulin
intraven
may
antagon
tnf
also
interfer
myelinspecif
antibodi
antimog
antibodi
engulf
myelin
membran
macrophag
via
coat
pit
aminoguanidin
inhibitor
induc
synthas
suppress
secret
toxic
nitrogen
intermedi
effect
treat
eae
recent
attempt
treat
ms
focus
gener
immunosuppress
drug
sinc
diseas
presum
immunolog
mediat
although
drug
may
effect
diseas
process
clinic
trial
often
inconclus
discourag
last
year
attent
direct
therapi
modifi
tmc
specif
manner
similar
seen
experiment
model
eae
howev
sinc
target
antigen
antigen
ms
known
sinc
restrict
tcr
usag
often
found
experiment
anim
gener
found
ms
approach
difficult
initi
ms
thu
recent
treatment
approach
begun
focu
modifi
biolog
ms
lesion
despit
inabl
identifi
caus
ms
understand
event
involv
evolut
ms
lesion
increas
turn
led
number
innov
therapi
ms
target
process
involv
lesion
develop
rather
precis
caus
diseas
earli
step
import
activ
autoreact
cell
approach
rang
attempt
alter
event
bbb
downregul
proinflammatori
cytokin
enhanc
cytokin
thought
downregul
delet
effector
mechan
lesion
current
studi
examin
effect
block
tnfcdlt
administ
regulatori
cytokin
tgffl
way
final
despit
fact
uniqu
trimolecular
interact
yet
demonstr
pathogenesi
ms
evid
immunodomin
peptid
autoantigen
recogn
context
diseaseassoci
hla
class
ii
molecul
particularli
earli
phase
diseas
cell
respons
may
primarili
direct
mhc
peptid
complex
studi
requir
cell
activ
indic
modif
amino
acid
import
tcr
contact
encephalitogen
peptid
therapeut
modifi
cell
respons
approach
potenti
target
cell
may
regulatori
suppress
function
lesion
downregul
inflammatori
activ
lesion
regardless
initi
antigen
similar
mechan
may
achiev
oral
toler
thu
despit
continu
uncertainti
regard
caus
ms
improv
understand
pathogenet
process
eae
ms
result
innov
therapi
hold
hope
effect
treatment
diseas
